BIOT 220 |
| Yield of monoclonal antibody production from mammalian cell culture systems has been steadily on the rise over the past two decades. In addition to improvements in host cell/clone selection and vector construction, nutritional improvements in cell culture processes contribute significantly to this productivity enhancement. With metabolic knowledge of industrial relevant cell lines (e.g. NS0 and CHO) accumulated over decades of use, the reality of a wholly chemically defined process has been achieved. In many cases the chemically defined processes have demonstrated high productivity. The development of high-producing chemically defined processes will further enrich our knowledge of nutrient requirements, as well as regulation of cellular metabolism and protein production. This knowledge will drive a positive feedback loop between improving cell biology understanding and improving productivity through rational medium/nutrient feed design. The development and implementation of a chemically defined GS-CHO platform process for mAb production in Pfizer Global Biologics will be presented. The beneficial effects and some challenges will be discussed. |
|
Commercialization of Biologics: Characterization and Improvement of Platforms to Aid Commercialization of Biologics
3:00 PM-5:20 PM, Wednesday, August 22, 2007 BCEC -- 107C, Oral
Division of Biochemical Technology |